Background: Vitamin K antagonists (VKA) remain widely used in the treatment of venous thromboembolism (VTE). During surgical interventions, the prevention of recurrent VTE must be weighed against the increased bleeding risk conferred by anticoagulation. There is a lack of strong evidence to guide the optimal periprocedural management of anticoagulation in patients with prior VTE, and [...]

Background: Venous thromboembolism (VTE) in hospitalized medically ill patients is a leading preventable cause of morbidity and mortality in the United States. About half of VTE events occur following discontinuation of standard-duration in-hospital prophylaxis and hospital discharge. The APEX study evaluated Betrixaban for in-hospital to home VTE prophylaxis and is the first FDA approved anticoagulant [...]

Background: Venous thromboembolism (VTE) in hospitalized medically ill patients is a leading preventable cause of morbidity and mortality in the United States. About half of VTE events occur following discontinuation of standard-duration in-hospital prophylaxis and hospital discharge. The APEX study evaluated Betrixaban for in-hospital to home VTE prophylaxis and is the first FDA approved anticoagulant [...]

Background: Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, is a serious public health problem causing over 90,000 deaths each year. VTE rates at our institution have been high and costly, with insurer penalties for post-operative VTE exceeding $5.5M in 2014. While prophylaxis for at-risk inpatients can reduce hospital-associated (HA) VTE by up [...]

Background: Mobile health applications have the potential to support patients via improved engagement and self-management. While the use of this technology has been developed for patients with chronic diseases, there is limited evidence to guide the development of this technology for patients with acute conditions. Patients diagnosed with acute venous thromboembolic disease (VTE) are at [...]